This is a working overview of 反相高效液相色谱, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-09 and is reviewed periodically as new material appears.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Going back more than 350 years, the first landmark description was of general blood circulation by William Harvey in 1628, which formed the anatomical basis for intravenous infusions. Investigations during the following centuries demonstrated solutions containing electrolytes and glucose could be given intravenously. The accumulated knowledge of protein metabolism formed the basis for studies on intravenous nutrition with protein hydrolysates, peptides, and amino acids. Robert Elman's observation in the late 1930s that amino acids in the form of protein hydrolysate could be administered safely was the first major step toward TPN. During the following years, major efforts were made to find methods to prepare infusion solutions with a high energy content and low osmotic pressure. The most realistic alternative seemed to be fat in the form of an emulsion. Many studies of a large number of various fat emulsions were made from the 1920s until the end of the 1950s. However, all of these emulsions caused severe adverse reactions. The first safe fat emulsion, Intralipid, developed by Prof. Arvid Wretlind of the Karolinska Institute, Sweden, was made available for clinical use in 1962. This was the second major step toward TPN. Vitamins, electrolytes, and trace elements were then included in the fat emulsions and in the solutions of amino acids and glucose. Later in the 1960s, Dr. Stanley Dudrick, who as a surgical resident in the University of Pennsylvania, working in the basic science laboratory of Dr.
Crustacean cardioactive peptide (CCAP) is a highly conserved, amidated cyclic nonapeptide with the primary structure PFCNAFTGC-NH2 (ProPheCysAsnAlaPheThrGlyCys-NH2) and a disulfide bridge between Cys3 and Cys9. It is found in crustaceans and insects where it behaves as a cardioaccelerator, neuropeptide transmitter for other areas of the nervous system and a hormone. CCAP was first isolated from the pericardial organs of the shore crab Carcinus maenas, where it has a role in regulating heartbeat. It was assumed that this was the peptide's main function and its name reflects this.
== Etymology, usage, and history of -gate == The suffix -gate derives from the Watergate scandal in the United States in the early 1970s, which resulted in the resignation of US President Richard Nixon. The scandal was named after the Watergate complex in Washington, D.C., where the burglary giving rise to the scandal took place; the complex itself was named after the "Water Gate" area where symphony orchestra concerts were staged on the Potomac River between 1935 and 1965. The suffix has become productive as a libfix and is used to embellish a noun or name to suggest the existence of a far-reaching scandal, particularly in politics and government. As a CBC News column noted in 2001, the term may "suggest unethical behavior and a cover-up". The use of “—gate” served well in an era of sound bites politics. Because they were short and memorable, these phrases caught the attention of the public — and because of its origin [Watergate] it carried a stigma around it, making lesser-known scenarios seem more important. Such usage has been criticized by some commentators as clichéd and misleading. James Stanyer comments that "revelations are given the 'gate' suffix to add a thin veil of credibility, following 'Watergate', but most bear no resemblance to the painstaking investigation of that particular piece of presidential corruption". Stanyer links the widespread use of -gate to what the sociologist John Thompson calls "scandal syndrome":
Sources: en.wikipedia.org
1993/638) Dunfermline and Kirkcaldy Districts (Mossmorran) Boundaries Amendment Order 1993 (S.I. 1993/639) Dumfries and Galloway and Strathclyde Regions and Cumnock and Doon Valley and Stewartry Districts (Loch Doon) Boundaries Amendment Order 1993 (S.I. 1993/640) Law Reform (Miscellaneous Provisions) (Scotland) Act 1990 (Commencement No. 11) Order 1993 (S.I. 1993/641) National Health Service (Travelling Expenses and Remission of Charges) (Scotland) Amendment Regulations 1993 (S.I. 1993/642) Glasgow Polytechnic and The Queen's College, Glasgow (Closure) (Scotland) Order 1993 (S.I. 1993/643) Local Authorities Etc. (Allowances) (Scotland) Amendment Regulations 1993 (S.I. 1993/644) Assured Tenancies (Rent Information) (Scotland) Amendment Order 1993 (S.I. 1993/645) Rent Officers (Additional Functions) (Scotland) Amendment Order 1993 (S.I. 1993/646) Rent Regulation (Forms and Information etc.) (Scotland) Amendment Regulations 1993 (S.I. 1993/647) Assured Tenancies (Forms) (Scotland) Amendment Regulations 1993 (S.I. 1993/648) Assured Tenancies (Rent Book) (Scotland) Amendment Regulations 1993 (S.I. 1993/649) Social Security (Payments on account, Overpayments and Recovery) Amendment Regulations 1993 (S.I. 1993/650) Local Government Finance (Housing) (Consequential Amendments) Order 1993 (S.I. 1993/651) Rent Officers (Additional Functions) (Amendment) Order 1993 (S.I. 1993/652) Rent Assessment Committees (England and Wales) (Amendment) Regulations 1993 (S.I. 1993/653) Assured Tenancies and Agricultural Occupancies (Forms) (Amendment) Regulations 1993 (S.I.
As of 2008, clinical evidence for pressure immobilization using an elastic bandage was limited. It is recommended as an immediate first-aid treatment for snakebites that have occurred in Australia (due to elapids which are neurotoxic). It is not recommended for bites from non-neurotoxic snakes such as those found in North America and some other regions of the world. The British military recommends pressure immobilization in all cases where the type of snake is unknown. Pressure immobilization is intended as an immediate first-aid measure to delay the systemic spread of venom and to buy time for medical assistance to be obtained. It does not replace definitive medical treatment. The technique aims to delay the movement of venom from a bitten limb through the lymphatic system, by applying pressure to restrict lymphatic drainage and immobilizing the bitten limb to reduce the pumping action of skeletal muscles. Because lymphatic flow is driven largely by muscle movements, the limb needs to be immobilised with a splint after the pressure bandage is applied.
Hakan Fidan, the Turkish foreign minister called the plans unacceptable. United Arab Emirates: Emirati ambassador to the US Yousef Al-Otaiba stated that he sees "no other alternatives" to Trump's proposal.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
反相高效液相色谱用于分离和纯度评估，质谱用于分子量确认。肽图谱或串联质谱可进一步验证序列。具体方法需根据样品基质和监管要求选择。